| DGH | PSUMMIT | |||
|---|---|---|---|---|
| (Ust 45mg) | (Ust 90mg) | (Ust 45mg) | (Ust 90mg) | |
| Week 24 withdrawal | 4/15 | 0/5 | 8/205 | 7/204 |
| Reasons: | ||||
| Adverse effects | 3 | 4 | 3 | |
| Inefficacy | 1 | 2 | 1 | |
| Other (consent, lost follow up) | 4 | 3 | ||
| Week 52 withdrawal | 0/8 | 0/3 | 17/197 | 15/197 |
| Reasons: | ||||
| Adverse effects | 2 | 5 | ||
| Inefficacy | 7 | 3 | ||
| Other (consent, lost follow up) | 8 | 7 | ||
Treatment Failure group (DGH): All patients had had at least one anti-TNF agent prior to Ustekinumab therapy. One patient had trialled 3, two had two, one had one. They had been stopped either due to inefficacy or intolerance.